-positive lung adenocatcinoma (ADC) patients. fusion status was examined by FISH and qRT-PCR assay. fusion were 100% and 85.1%, respectively. The total concordance rate between IHC and qRT-PCR were 93.3%.IHC is a reliable and rapid screening tool in routine pathologic laboratories for the identification of suitable candidates for ROS1-targeted therapy. Some ROS1 IHC-positive but FISH-negative cases did harbor the translocation events and may benefit from crizotinib
International audienceAnaplastic lymphoma kinase (ALK) gene rearrangements in lung adenocarcinoma re...
Rearrangements of the ROS1 gene occur in 1-2 % of non-small cell lung cancers (NSCLCs). Crizotinib, ...
OBJECTIVES: We aimed to determine the prevalence and partners of ROS1 rearrangements, to explore the...
<div><p>Aims</p><p>To compare fluorescence <i>in situ</i> hybridization (FISH), immunohistochemistry...
ROS1 gene rearrangements are reported in 1–2% of lung adenocarcinomas (ACA) and are associated with ...
Aims. To assess the prevalence of ROS1 rearrangements in a retrospective and prospective diagnostic ...
Abstract Sambit K. Mohanty ...
EML4-ALK is a new driver gene of non-small cell lung cancer and a target of crizotinib. The objectiv...
EML4-ALK is a new driver gene of non-small cell lung cancer and a target of crizotinib. The objectiv...
AIMS: To assess the prevalence of ROS1 rearrangements in a retrospective and prospective diagnostic ...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
<div><p><i>ROS1</i> rearrangement is a predictive biomarker for response to the tyrosine kinase inhi...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
AbstractBackgroundROS1 gene fusions cause several cancers by constitutively activating the ROS1 tyro...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
International audienceAnaplastic lymphoma kinase (ALK) gene rearrangements in lung adenocarcinoma re...
Rearrangements of the ROS1 gene occur in 1-2 % of non-small cell lung cancers (NSCLCs). Crizotinib, ...
OBJECTIVES: We aimed to determine the prevalence and partners of ROS1 rearrangements, to explore the...
<div><p>Aims</p><p>To compare fluorescence <i>in situ</i> hybridization (FISH), immunohistochemistry...
ROS1 gene rearrangements are reported in 1–2% of lung adenocarcinomas (ACA) and are associated with ...
Aims. To assess the prevalence of ROS1 rearrangements in a retrospective and prospective diagnostic ...
Abstract Sambit K. Mohanty ...
EML4-ALK is a new driver gene of non-small cell lung cancer and a target of crizotinib. The objectiv...
EML4-ALK is a new driver gene of non-small cell lung cancer and a target of crizotinib. The objectiv...
AIMS: To assess the prevalence of ROS1 rearrangements in a retrospective and prospective diagnostic ...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
<div><p><i>ROS1</i> rearrangement is a predictive biomarker for response to the tyrosine kinase inhi...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
AbstractBackgroundROS1 gene fusions cause several cancers by constitutively activating the ROS1 tyro...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
International audienceAnaplastic lymphoma kinase (ALK) gene rearrangements in lung adenocarcinoma re...
Rearrangements of the ROS1 gene occur in 1-2 % of non-small cell lung cancers (NSCLCs). Crizotinib, ...
OBJECTIVES: We aimed to determine the prevalence and partners of ROS1 rearrangements, to explore the...